MétaCan
Menu
Retour à la cohorte
Enregistrement W4253382278 · doi:10.4161/cbt.8.19.10099

Walter J. Curran, MD, appointed Emory Winship Cancer Institute Executive Director

2009· article· en· W4253382278 sur OpenAlexaboutno aff

Notice bibliographique

RevueCancer Biology & Therapy · 2009
Typearticle
Langueen
DomaineMedicine
ThématiqueAdvances in Oncology and Radiotherapy
Établissements canadiensnon disponible
Organismes subventionnairesWinship Cancer InstituteNational Cancer InstituteEmory University
Mots-clésCurranMedicineExecutive directorManagement

Résumé

récupéré en direct d'OpenAlex

AbstractBrian Leyland-Jones steps down to pursue research interests Walter J. Curran, MD, has been named executive director of the Emory Winship Cancer Institute, succeeding Brian Leyland-Jones, MD, PhD, who stepped down to pursue research interests. Curran, a Georgia Cancer Coalition Distinguished Scholar, has served as the Lawrence W. Davis Professor and Chairman of Emory's Department of Radiation Oncology and as chief medical officer of Emory Winship. Curran joined Emory in January 2008, from Jefferson Medical College in Philadelphia, where he served as professor and chair of the Department of Radiation Oncology and clinical director for Jefferson's Kimmel Cancer Center. He currently serves as Group Chairman and Principal Investigator of the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded cooperative group, a position he has held since 1997. Leyland-Jones joined Emory as director of the Emory Winship Cancer Institute in January 2007. "I am very proud of Winship's recent National Cancer Institute Cancer Center Designation," says Leyland-Jones. "Now that we have accomplished this significant goal, I look forward to concentrating on my long time research interests in personalized translational medicine as an Emory School of Medicine faculty member." Leyland-Jones will be a professor of hematology and medical oncology at EWCI. Emory Winship announced its NCI designation earlier this year, joining an elite cadre of 65 cancer centers around the country. Emory Winship is the first facility in Georgia to earn this designation. "Emory Winship is a leader in the fight against cancer on multiple fronts - research, education, prevention and patient care," says Fred Sanfilippo, MD, PhD, executive vice president for health affairs at Emory University. "We appreciate Dr. Leyland-Jones' many contributions and will continue this positive trajectory in cancer treatment and research at the Woodruff Health Sciences Center under Dr. Curran's leadership." "We have made great strides as a center," says Curran, "and Emory Winship will continue to emphasize outstanding multidisciplinary care and research. Our greatest strength lies in how our entire team works together on behalf of our patients." "We appreciate Dr. Leyland-Jones' good work and look forward to continued success in working with Dr. Curran," says Bill Todd, president and CEO of the Georgia Cancer Coalition. "Dr. Curran's focus on team-based care combined with groundbreaking science will benefit patients in Atlanta, throughout Georgia and beyond." Curran has been a principal investigator on several National Cancer Institute grants and is considered an international expert in the management of patients with locally advanced lung cancer and malignant brain tumors. He has led several landmark clinical and translational trials in both areas and is responsible for defining a universally adopted staging system for patients with malignant glioma. He has authored or co-authored more than four hundred abstracts and scholarly papers, as well as numerous presentations, reviews and book chapters. He has been chairman or co-chairman of more than 40 clinical trials and a reviewer for twelve national/international journals. He serves as the Founding Secretary/Treasurer of the Coalition of Cancer Cooperative Groups and a Board Member of the Georgia Center for Oncology Research and Education (Ga CORE). Curran is a Fellow in the American College of Radiology and has been awarded honorary memberships in the European Society of Therapeutic Radiology and Oncology and the Canadian Association of Radiation Oncology. In 2006, he was named the leading radiation oncologist/cancer researcher in a peer survey by the journal Medical Imaging. Under Curran's leadership Emory's Radiation Oncology Department has been recently selected as a "Top Five Radiation Therapy Centers to Watch in 2009" by Imaging Technology News. This review recognizes the most forward-thinking, U.S.-based cancer treatment centers, which have adopted advanced technology to optimize treatment and make a difference in patient care. Curran graduated cum laude from Dartmouth College, received his MD degree from the Medical College of Georgia and is a Board Certified Radiation Oncologist. Curran completed his residency in the Department of Radiation Therapy at the University of Pennsylvania Medical Center and his internship in internal medicine at Presbyterian University of Pennsylvania Medical Center in Philadelphia. The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focused on missions of teaching, research, health care and public service. Its components include the Emory University School of Medicine, Nell Hodgson Woodruff School of Nursing, and Rollins School of Public Health; Yerkes National Primate Research Center; Emory Winship Cancer Institute; and Emory Healthcare, the largest, most comprehensive health system in Georgia. Emory Healthcare includes: The Emory Clinic, Emory-Children's Center, Emory University Hospital, Emory University Hospital Midtown, Wesley Woods Center, Emory University Orthopaedics & Spine Hospital, the jointly owned Emory-Adventist Hospital, and EHCA, a limited liability company created with Hospital Corporation of America. EHCA includes two joint venture hospitals, Emory Eastside Medical Center and Emory Johns Creek Hospital. The Woodruff Health Sciences Center has a $2.3 billion budget, 18,000 employees, 2,500 full-time and 1,500 affiliated faculty, 4,300 students and trainees, and a $5.5 billion economic impact on metro Atlanta.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,006
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: Sans objet
GenreSignal candidat: Autre · Signal consensuel: Autre
Score de désaccord entre enseignants0,135
Score d'incertitude au seuil0,451

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0020,006
Méta-épidémiologie (sens strict)0,0010,000
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0020,001
Études des sciences et des technologies0,0020,000
Communication savante0,0040,001
Science ouverte0,0010,001
Intégrité de la recherche0,0020,004
Charge utile insuffisante (le modèle a refusé de juger)0,1350,054

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,043
Tête enseignante GPT0,428
Écart entre enseignants0,385 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeSans objet
Domainenon disponible
GenreAutre

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2009
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueCancer Biology & TherapyMême sujetAdvances in Oncology and RadiotherapyTravaux en français237 207